论文部分内容阅读
为了评价氧哌羟苯唑头孢菌素(cefoperazone,下称CPZ)每天给药2次的安全性和临床效果,一个由全美国187位研究者组成的合作组进行了多中心的临床试验.659例病人静脉或肌肉注射CPZ钠盐,通常剂量为每次2g,每天2次,连续6周,个别患者的每次剂量≥4g.评价的455例感染病人(男229,女226,平均年龄60岁),每天接受的剂量≤4g者占91.4%,治疗成功率为95.3%.各种感染的临床效果如下:呼吸道感染100例,总有效率95%.其中肺炎73例,
In order to evaluate the safety and clinical efficacy of cefoperazone (CPZ) administered twice daily, a collaborative group of 187 researchers across the United States conducted a multicenter clinical trial.665 Patients with intravenous or intramuscular injection of CPZ sodium salt, the usual dose of 2g, 2 times a day for 6 weeks, each individual dose ≥ 4g. Evaluation of 455 cases of infected patients (229, 226, mean age 60 Year), the daily dose of ≤ 4g accounted for 91.4%, the success rate was 95.3% .The clinical effects of various infections are as follows: 100 cases of respiratory tract infection, the total effective rate of 95% of which 73 cases of pneumonia,